| Dr Joel Guss, MD | |
|
1425 S Main St, Dept. Of Head & Neck Surgery, Walnut Creek, CA 94596-5318 | |
| (925) 295-4100 | |
| Not Available |
| Full Name | Dr Joel Guss |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 21 Years |
| Location | 1425 S Main St, Walnut Creek, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1962568881 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207YX0905X | Otolaryngology - Otolaryngology/facial Plastic Surgery | A 107626 (California) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Permanente Medical Group Inc | 8921910225 | 7800 |
News Archive
Scientists at Winship Cancer Institute of Emory University have mapped a vast spider web of interactions between proteins in lung cancer cells, as part of an effort to reach what was considered "undruggable."
Imagine a future where a guided biomachine put into your body seeks out defective gene sequences in each cell and edits in the correct information with precision accuracy.
Human-specific variants of four microRNAs may have altered expression levels and gene targets compared to other great apes, according to a study published April 22, 2016 in the open-access journal PLOS ONE by Alicia Gallego from the Institute of Evolutionary Biology, Spain, and colleagues.
ArQule, Inc. today announced the presentation of Phase 1 results of a clinical trial among patients with metastatic colorectal cancer (CRC) treated with ARQ 197, a selective small molecule inhibitor of the c-MET receptor tyrosine kinase, in combination with irinotecan and cetuximab. ARQ 197 is under development by Daiichi Sankyo Co., Ltd. and ArQule.
› Verified 5 days ago
| Entity Name | Permanente Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073606299 PECOS PAC ID: 8921910225 Enrollment ID: O20031104000710 |
News Archive
Scientists at Winship Cancer Institute of Emory University have mapped a vast spider web of interactions between proteins in lung cancer cells, as part of an effort to reach what was considered "undruggable."
Imagine a future where a guided biomachine put into your body seeks out defective gene sequences in each cell and edits in the correct information with precision accuracy.
Human-specific variants of four microRNAs may have altered expression levels and gene targets compared to other great apes, according to a study published April 22, 2016 in the open-access journal PLOS ONE by Alicia Gallego from the Institute of Evolutionary Biology, Spain, and colleagues.
ArQule, Inc. today announced the presentation of Phase 1 results of a clinical trial among patients with metastatic colorectal cancer (CRC) treated with ARQ 197, a selective small molecule inhibitor of the c-MET receptor tyrosine kinase, in combination with irinotecan and cetuximab. ARQ 197 is under development by Daiichi Sankyo Co., Ltd. and ArQule.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Joel Guss, MD 1425 S Main St, Dept. Of Head & Neck Surgery, Walnut Creek, CA 94596-5318 Ph: () - | Dr Joel Guss, MD 1425 S Main St, Dept. Of Head & Neck Surgery, Walnut Creek, CA 94596-5318 Ph: (925) 295-4100 |
News Archive
Scientists at Winship Cancer Institute of Emory University have mapped a vast spider web of interactions between proteins in lung cancer cells, as part of an effort to reach what was considered "undruggable."
Imagine a future where a guided biomachine put into your body seeks out defective gene sequences in each cell and edits in the correct information with precision accuracy.
Human-specific variants of four microRNAs may have altered expression levels and gene targets compared to other great apes, according to a study published April 22, 2016 in the open-access journal PLOS ONE by Alicia Gallego from the Institute of Evolutionary Biology, Spain, and colleagues.
ArQule, Inc. today announced the presentation of Phase 1 results of a clinical trial among patients with metastatic colorectal cancer (CRC) treated with ARQ 197, a selective small molecule inhibitor of the c-MET receptor tyrosine kinase, in combination with irinotecan and cetuximab. ARQ 197 is under development by Daiichi Sankyo Co., Ltd. and ArQule.
› Verified 5 days ago
Glenn D. Schneider, MD Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 1425 S Main St, Walnut Creek, CA 94596 Phone: 925-295-4000 | |
Bryan Philip Fong, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1425 S Main St, Walnut Creek, CA 94596 Phone: 925-295-4000 | |
Dr. Rahul Seth, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 355 Lennon Ln Ste 235, Walnut Creek, CA 94598 Phone: 925-357-9050 Fax: 925-357-9040 | |
Nicole Daamen, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1425 S Main St, Walnut Creek, CA 94596 Phone: 925-295-4000 | |
Erica Christine Bennett, MD Otolaryngology Medicare: Medicare Enrolled Practice Location: 106 La Casa Via Ste 100, Walnut Creek, CA 94598 Phone: 925-239-2900 | |
Dr. Sarah Syed Connell, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1425 S Main St, Walnut Creek, CA 94596 Phone: 925-295-4100 Fax: 925-295-5414 | |
Cornelius J.a. Jansen, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1425 S Main St, Walnut Creek, CA 94596 Phone: 925-295-4000 |